To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation, we studied 51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients. A total of 12 recipients were at moderate risk for CMV disease and 39 were at high risk. Conditioning regimens varied, but GvHD prophylaxis consisted of tacrolimus and mini-methotrexate in all patients. All patients received prophylactic ganciclovir from admission until day À2 and prophylactic acyclovir from day À1 until day 180 after transplantation. CMV viremia was treated with ganciclovir. Using a PCR-based technique, the cumulative incidence of CMV viremia was 31714% by day 100 and 35714% by day 150. Donor type, CMV risk group, underlying disorder, conditioning regimen, GvHD, and steroid use were not associated with the risk for CMV viremia. No cases of CMV disease occurred. We hypothesize that the low rate of CMV viremia and the absence of CMV disease in this cohort of PBSCT transplant recipients, which contrasts with other reports, may be related to the prophylactic use of highdose acyclovir and possibly to pretransplant use of ganciclovir.
plantation G-CSF mobilized peripheral blood stem cell (PBSC) transplantation, although introduced recently, is widely used in allogeneic transplantation. 1, 2 The altered patterns of hematopoietic and immune recovery after stem cell transplantation may affect the incidence of CMV viremia and disease, as may the increased number of WBC infused with a PBSC graft. 3, 4 On the other hand, most data on incidence and management of CMV viremia and disease come from allogeneic bone marrow transplant recipients undergoing myeloablative conditioning. 5 We report the incidence of CMV viremia in 51 consecutive patients who received allogeneic G-CSF mobilized PBSC transplantation and post-transplant G-CSF. In all, 22 of these patients received classic conditioning regimens, the remainder received melphalan or cyclophosphamide-based conditioning regimens. The cumulative incidence of CMV viremia in this series was only 31714% at day 100 post-transplant, and among 38 patients surviving beyond day 100, no cases of CMV disease were observed. We hypothesize that our use of prophylactic pretransplant ganciclovir and prolonged post-transplant acyclovir contributed to a reduced incidence of CMV viremia and disease.
Patients and methods
A total of 62 consecutive patients underwent allogeneic PBSC transplantation from April 1997 to August 2000. Only 51 patients who were either seropositive for CMV pretransplant or had seropositive donors were included in this analysis. A total of 12 patients were at moderate (donor CMV seropositive, recipient negative) risk for CMV disease and 39 were at high risk (recipient CMVseropositive). Patient characteristics, type of transplant and preparative regimens are listed in Table 1 . The median age was 44 years . In all, 45 patients had hematological malignancies, three had myelofibrosis, one had aplastic anemia and 2 patients had sickle cell disease. Five patients had had a previous transplant. A total of 48 patients received stem cells from a matched sibling and three received stem cells from a matched unrelated donor. Conditioning consisted of fludarabine/thiotepa/TBI in 21, Patient samples were tested for CMV DNA in peripheral blood leucocytes (PBL) by a PCR-assay with primers specific to the major intermediate -early gene region of the CMV genome that yielded a 147 bp product. Primers for the human P53 exon 5 gene sequence were employed as an internal control. The PCR-assay (QPCR SYSTEM 5000 # ) was based on the relative luminosity recorded after labeling the PCR products with luminescent probes. The result was reported as negative, equivocal or positive depending on the relative luminosity recorded. Specificity was determined by testing 50 healthy volunteers, 25 of whom were CMV seropositive. The assay was negative in all 50 subjects, indicating a very high specificity. The assay was consistently positive in control samples that contained five copies of CMV DNA/ml blood indicating high sensitivity. Control samples with five and 50 copies of CMV/ml were included as positive controls in each assay run.
Patients were monitored weekly for CMV by PCR for the first 100 days after transplantation. After 100 days posttransplant, the patients were tested by CMV-PCR at each clinic visit. Ganciclovir 5 mg/kg i.v. b.i.d. for 14 days was started on the first day of PCR positivity. If the CMV-PCR assay remained positive after two weeks, ganciclovir was continued for an additional 2 weeks. Foscarnet at 60 mg/kg i.v. q 8 h was utilized for patients remaining PCR positive after 4 weeks of treatment.
The cumulative incidence for CMV viremia was calculated by using the method of Kaplan and Meier. Patients who died or experienced disease recurrence were censored. The Log-rank test was used to determine the association of CMV viremia with the following parameters: age, CMV risk status (high vs intermediate), gender, donor type, pretransplant diagnosis, conditioning regimen (ie myeloablative vs nonmyeloablative), GvHD, and steroid use.
Results
Out of 51 patients, 21 developed CMV viremia posttransplant. The cumulative incidence of CMV viremia was 31714% at day 100 and 35714% at day 180 posttransplantation ( Figure 1 ). Once patients had become CMV viremic, it took an average of 11 days (range [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] for CMV viremia to clear with treatment. No cases of CMV disease were observed in the first 100 days posttransplant. No cases of delayed CMV disease were observed among 38 patients who survived beyond 100 days after transplantation.
The incidence of CMV positivity and the time to CMV positivity was similar between those receiving TBI-based conditioning and those receiving nonmyeloablative regimens. It was also similar among moderate-and highrecipients. No other patient-, disease-or treatment-related features were associated with an altered risk of CMV viremia.
Discussion
In a recent report on 46 North American PBSC transplant recipients, the incidence of CMV viremia was 63% by day 100 and the incidence of CMV disease was 15%, higher than in a control group undergoing bone marrow transplantation. 10 In another recent report from Seattle, the cumulative incidences of CMV in PBSC transplant recipients were 78 and 53% in myeloablative and nonmyeloablative conditioning regimens, respectively.
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In several other recent North American studies, using PBSC transplantation, a cumulative incidence of CMV disease of 10-25% has been reported. This is at least as high and possibly higher than that in patients undergoing bone marrow transplantation and there is some concern over an increased risk of CMV viremia related to the high WBC content of peripheral stem cell collections. [10] [11] [12] In contrast, several European studies indicate an extremely low risk of CMV disease by day 100 after both stem cell and bone marrow transplantation and an extremely low overall cumulative risk of CMV disease. 13, 14 We hypothesize that the low incidence of CMV viremia and disease in our series of stem cell transplant recipients, 3 (6) and the wide variation in observed incidences of CMV viremia and especially of CMV disease after stem cell transplantation is related to antiviral prophylaxis as also recently reported by Nakamura et al. 15 We routinely administered pretransplant ganciclovir followed by highdose i.v. acyclovir from day À1 until discharge and acyclovir 800 mg p.o. b.i.d. or t.i.d. from discharge until day 180 post-transplantation. Pretransplant ganciclovir has been used by several groups in the early 90 s, and is likely to have an impact on post-transplant incidence of CMV viremia or to prevent rare cases of early CMV reactivation. [16] [17] [18] Others have used pretransplant acyclovir for similar purposes. 15 More importantly, the prolonged use of high-dose acyclovir after transplantation is likely to have contributed to the absence of CMV disease. High-dose acyclovir has repeatedly been shown to decrease the incidence of CMV reactivation and disease after bone marrow transplantation, 19, 20 Its use in the ganciclovir era is recommended by many centers in Europe, 20, 21 but is not favored in many North American centers. 22 This reluctance is partly due to the fact that the drug has not been shown to have an impact on survival, when pre-emptive treatment with ganciclovir is used, and partly due to the initial difficulty in reconciling an important in vivo effect with limited and unexplained in vitro efficacy. It has, however, recently been shown that acyclovir can be phosphorylated by the UL97 gene product of CMV, providing a rationale to the observed in vivo activity in various patient populations. 23 In a recent randomized multicenter study, the achievement of higher blood levels of acyclovir by the use of its highly bioavailable prodrug valacyclovir was associated with further reductions and delays in CMV reactivation and disease. 13 Again, no survival advantage or reduction in the already very low incidence of CMV disease could be shown in the valacyclovir group. Nevertheless, any reduction in incidence of CMV reactivation or viremia results in decreased utilization of pre-emptive treatment with ganciclovir or foscarnet, two potentially toxic drugs. While the dose of p.o. acyclovir utilized by our group is not as high as used in European studies, such doses do have modest anti-CMV activity, and in combination with a strategy of preemptive treatment likely have contributed to the avoidance of CMV disease. 24 Approximately half of the patients in our series received myeloablative conditioning, and 18 received fludarabinemelphalan. While the number of patients is relatively small, the incidence of CMV viremia after fludarabine-melphalan conditioning was equivalent to that after myeloablative conditioning. This is consistent with reports from other groups, indicating a similar overall incidence of CMV viremia after melphalan or fludarabine-melphalan-based conditioning, 25, 26 or other nonmyeloablative conditioning regimens. 11, 12 In a recent report from Seattle, a delay in time to CMV viremia was documented after nonmyeloablative transplantation, but the overall incidence was unchanged.
11 Our inability to detect a similar delay may be either due to the relatively small number of patients undergoing nonmyeloablative transplantation or due to our use of the fludarabine-melphalan regimen, which is considerably more myelosuppressive than fludarabine combined with low-dose TBI.
In summary, the incidence of CMV viremia and CMV disease in this series compares favorably to other reports on allogeneic PBSC transplants. Differences in supportive care and in particular the prolonged use of acyclovir post-transplant are likely to have contributed to the low incidence of CMV viremia and disease. We recommend the routine use of post-transplant acyclovir or its better absorbed analogue valacyclovir for patients undergoing allogeneic PBSC transplantation. Incidence of CMV viremia after cell transplantation A Verma et al
